Log in

SYNACT SynAct Pharma AB OMXSTO · Sweden

SynAct Pharma AB (SYNACT) news

SynAct Pharma AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker SYNACT, recorded under Sweden. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest SynAct Pharma AB news

We have not published a story on SynAct Pharma AB yet. When there is news, it will appear here.

Questions about SynAct Pharma AB

What is the ticker symbol of SynAct Pharma AB?

SynAct Pharma AB trades under the ticker SYNACT on OMXSTO.

Where is SynAct Pharma AB listed?

SynAct Pharma AB is listed on OMXSTO. Our directory also records these other listings: GETTEX:8F8.

Which country or territory is SynAct Pharma AB listed under?

Our directory records SynAct Pharma AB under Sweden.

What does SynAct Pharma AB do?

Our directory classifies SynAct Pharma AB as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of SynAct Pharma AB?

The ISIN recorded for SynAct Pharma AB is SE0008241491.

Does aibio.space cover SynAct Pharma AB?

aibio.space lists SynAct Pharma AB among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to SynAct Pharma AB?

Companies in our directory listed in the same country and business area as SynAct Pharma AB: APTAHEM AB, Coegin Pharma AB, Cereno Scientific AB, Diamyd Medical AB, Immunovia AB, Swedencare AB.

Investor discussion: SynAct Pharma AB

Members talk about SynAct Pharma AB (SYNACT). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OMXSTO:SYNACT on TradingView.

Listing details

SynAct Pharma AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker SYNACT, recorded under Sweden. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
SynAct Pharma AB
Ticker
SYNACT
Listing
OMXSTO
Country or territory
Sweden
Business scope
Pharmaceuticals: Major
ISIN
SE0008241491
Other listed symbols
GETTEX:8F8
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.